CA2923010C - Thermally stable vaccine formulations and microneedles - Google Patents

Thermally stable vaccine formulations and microneedles Download PDF

Info

Publication number
CA2923010C
CA2923010C CA2923010A CA2923010A CA2923010C CA 2923010 C CA2923010 C CA 2923010C CA 2923010 A CA2923010 A CA 2923010A CA 2923010 A CA2923010 A CA 2923010A CA 2923010 C CA2923010 C CA 2923010C
Authority
CA
Canada
Prior art keywords
composition
vaccine composition
influenza
maltodextrin
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2923010A
Other languages
English (en)
French (fr)
Other versions
CA2923010A1 (en
Inventor
Matthew Joseph MISTILIS
William Christopher EDENS
Andreas Sebastian Bommarius
Mark Prausnitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georgia Tech Research Corp
Original Assignee
Georgia Tech Research Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgia Tech Research Corp filed Critical Georgia Tech Research Corp
Publication of CA2923010A1 publication Critical patent/CA2923010A1/en
Application granted granted Critical
Publication of CA2923010C publication Critical patent/CA2923010C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16311—Influenzavirus C, i.e. influenza C virus
    • C12N2760/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
CA2923010A 2013-09-03 2014-09-03 Thermally stable vaccine formulations and microneedles Active CA2923010C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361873032P 2013-09-03 2013-09-03
US61/873,032 2013-09-03
US201361873419P 2013-09-04 2013-09-04
US61/873,419 2013-09-04
PCT/US2014/053902 WO2015034924A1 (en) 2013-09-03 2014-09-03 Thermally stable vaccine formulations and microneedles

Publications (2)

Publication Number Publication Date
CA2923010A1 CA2923010A1 (en) 2015-03-12
CA2923010C true CA2923010C (en) 2022-08-30

Family

ID=52628897

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2923010A Active CA2923010C (en) 2013-09-03 2014-09-03 Thermally stable vaccine formulations and microneedles

Country Status (8)

Country Link
US (1) US10736840B2 (enExample)
EP (1) EP3041504B1 (enExample)
JP (2) JP6611720B2 (enExample)
CN (1) CN105579059B (enExample)
CA (1) CA2923010C (enExample)
ES (1) ES2897659T3 (enExample)
RU (1) RU2720808C2 (enExample)
WO (1) WO2015034924A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0402131D0 (en) 2004-01-30 2004-03-03 Isis Innovation Delivery method
US11179553B2 (en) 2011-10-12 2021-11-23 Vaxxas Pty Limited Delivery device
EP3134385A1 (en) 2014-04-25 2017-03-01 Ajinomoto Co., Inc. Immunostimulating agent
EP4218892A1 (en) 2015-02-02 2023-08-02 Vaxxas Pty Limited Microprojection array applicator
US20160296149A1 (en) * 2015-04-08 2016-10-13 Sandia Corporation In Vivo Extraction of Interstitial Fluid Using Hollow Microneedles
CN104984357B (zh) 2015-06-02 2018-01-30 长春百克生物科技股份公司 不含明胶的疫苗保护剂组合物及流感减毒活疫苗
WO2017045031A1 (en) 2015-09-18 2017-03-23 Vaxxas Pty Limited Microprojection arrays with microprojections having large surface area profiles
AU2016333148B2 (en) 2015-09-28 2021-10-14 Vaxxas Pty Limited Microprojection arrays with enhanced skin penetrating properties and methods thereof
EA036412B1 (ru) * 2015-10-06 2020-11-09 Янссен Вэксинс Энд Превеншн Б.В. Способ обеспечения защиты аденовируса от разрушения, вызванного взаимодействием с пластиком, и применение 2-гидроксипропил--циклодекстрина для защиты аденовируса
JP2018536645A (ja) 2015-10-28 2018-12-13 味の素株式会社 免疫賦活剤
US10744197B2 (en) * 2015-11-27 2020-08-18 Nitto Denko Corporation Vaccine pharmaceutical composition for oral administration and method for manufacturing vaccine pharmaceutical composition for oral administration
US10722570B2 (en) * 2015-11-27 2020-07-28 Nitto Denko Corporation Dried influenza vaccine preparation and method for producing dried influenza vaccine preparation
WO2017090767A1 (ja) * 2015-11-27 2017-06-01 日東電工株式会社 インフルエンザワクチン乾燥製剤、及び、インフルエンザワクチン乾燥製剤の製造方法
US10022436B2 (en) 2016-01-11 2018-07-17 Verndari, Inc. Microneedle compositions and methods of using same
ES2935202T3 (es) 2016-03-01 2023-03-02 Georgia Tech Res Inst Partículas de microagujas y composiciones para administrar una sustancia de interés
EP4306803B1 (en) 2017-03-31 2026-05-06 Vaxxas Pty Limited Device and method for coating surfaces
US11175128B2 (en) 2017-06-13 2021-11-16 Vaxxas Pty Limited Quality control of substrate coatings
AU2018309562A1 (en) 2017-08-04 2020-02-20 Vaxxas Pty Limited Compact high mechanical energy storage and low trigger force actuator for the delivery of microprojection array patches (MAP)
US20200246450A1 (en) * 2017-08-10 2020-08-06 Vaxxas Pty Limited Differential coating of microprojections and microneedles on arrays
CN110870913A (zh) * 2018-08-31 2020-03-10 成都夸常奥普医疗科技有限公司 氨基酸类营养素作为疫苗佐剂的应用以及包含氨基酸营养素作为佐剂的疫苗
AU2020222113B2 (en) * 2019-02-15 2026-07-16 Serum Institute Of India Pvt Ltd. Live attenuated influenza vaccine composition and process for preparation thereof
CN113677363B (zh) * 2019-03-28 2024-08-13 富士胶片株式会社 含有流感疫苗的微针阵列及微针阵列的制造方法
CA3135302A1 (en) * 2019-03-29 2020-10-08 Vaxxas Pty Limited Vaccination using high-density microprojection array patch
EP4061334A4 (en) * 2019-11-22 2024-02-14 Veradermics Incorporated MICRONEEDLE PATCH FOR THE ADMINISTRATION OF IMMUNO-STIMULATING MEDICATIONS
CN111154833B (zh) * 2020-01-03 2022-08-23 浙江夸克生物科技有限公司 一种α-L-岩藻糖苷酶测定试剂盒
WO2021252962A1 (en) * 2020-06-11 2021-12-16 Aquavit Pharmaceuticals, Inc, Methods and compositions for delivering bioactive compositions to ocular tissue using microneedle devices
CN114681605A (zh) * 2020-12-30 2022-07-01 辽宁成大生物股份有限公司 一种热稳定的手足口疫苗可溶性微针贴及其制备方法
CA3212891A1 (en) * 2021-03-23 2022-09-29 Veradermics Incorporated Perilesional treatment of skin conditions
IL313015A (en) * 2021-11-25 2024-07-01 Orexo Ab A pharmaceutical preparation that includes biopharmaceutical drug compounds
US20260007869A1 (en) 2023-06-23 2026-01-08 Vaxess Technologies, Inc. Microneedle array patches (maps), systems, and methods for manufacturing and using same
JPWO2025013783A1 (enExample) * 2023-07-07 2025-01-16
US20250325286A1 (en) * 2024-04-17 2025-10-23 Micron Biomedical, Inc. Methods and Microneedle Devices for Vaccinations with Enhanced Delivery and Acceptance
CN121971366B (zh) * 2026-01-27 2026-07-28 中国人民解放军疾病预防控制中心 一种猴痘疫苗可溶性微针贴及其制备方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6503231B1 (en) 1998-06-10 2003-01-07 Georgia Tech Research Corporation Microneedle device for transport of molecules across tissue
AU767122B2 (en) 1998-06-10 2003-10-30 Georgia Tech Research Corporation Microneedle devices and methods of manufacture and use thereof
US6743211B1 (en) 1999-11-23 2004-06-01 Georgia Tech Research Corporation Devices and methods for enhanced microneedle penetration of biological barriers
US6623457B1 (en) 1999-09-22 2003-09-23 Becton, Dickinson And Company Method and apparatus for the transdermal administration of a substance
US9302903B2 (en) 2000-12-14 2016-04-05 Georgia Tech Research Corporation Microneedle devices and production thereof
US6887484B2 (en) * 2001-07-31 2005-05-03 Posco Vaccine composition containing a promoter peptide
US6945952B2 (en) 2002-06-25 2005-09-20 Theraject, Inc. Solid solution perforator for drug delivery and other applications
AU2003275311A1 (en) 2002-09-16 2004-04-30 Sung-Yun Kwon Solid micro-perforators and methods of use
US7314613B2 (en) 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
US20050137525A1 (en) 2003-06-04 2005-06-23 Georgia Tech Research Corporation Drilling microneedle device
US9744227B2 (en) 2004-06-02 2017-08-29 Universal Stabilization Technologies, Inc. Compositions containing ambient-temperature stable, inactivated but therapeutically active biopharmaceuticals and methods for formulation thereof
GB0416694D0 (en) * 2004-07-27 2004-09-01 Univ Strathclyde Process for preparing microcrystals
WO2006128034A1 (en) 2005-05-25 2006-11-30 Georgia Tech Research Corporation Microneedles and methods for microinfusion
CA2612005C (en) 2005-06-17 2013-10-29 Georgia Tech Research Corporation Coated microstructures and method of manufacture thereof
ME01965B (me) 2005-09-16 2012-04-30 Merial Ltd Stabilizatori za vakcine osušene zamrzavanjem
US20090182306A1 (en) 2006-07-21 2009-07-16 Georgia Tech Research Corporation Microneedle Devices and Methods of Drug Delivery or Fluid Withdrawal
TWI428140B (zh) 2007-03-09 2014-03-01 Otsuka Pharma Co Ltd A freeze-dried preparation containing influenza vaccine and a method for producing the same
US8911749B2 (en) 2007-04-16 2014-12-16 Corium International, Inc. Vaccine delivery via microneedle arrays
GB0725018D0 (en) 2007-12-21 2008-01-30 Univ Cardiff Monitoring system for microneedle delivery
EP2254554A1 (en) 2008-02-25 2010-12-01 Novavax, Inc. Sugar glassified virus like particles (vlps)
CN105944095B (zh) * 2008-03-05 2021-04-02 赛诺菲巴斯德有限公司 一种使含佐剂的疫苗组合物稳定的方法
TWI489994B (zh) 2008-03-17 2015-07-01 Baxter Healthcare Sa 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
CN102076357A (zh) 2008-06-30 2011-05-25 久光制药株式会社 微针装置以及利用微针装置提高流感疫苗的功效性的方法
JP5671001B2 (ja) * 2009-03-26 2015-02-18 パルマトリックス，インコーポレイテッド 肺疾患を治療するための乾燥粉末製剤および方法
EP2459716B1 (en) * 2009-07-31 2016-08-17 Paxvax, Inc. Adenoviral-based vectors
US20110243988A1 (en) * 2009-10-01 2011-10-06 Aridis Pharmaceuticals Methods and Compositions for Stabilization of a Virus Vaccine
US8557253B2 (en) 2009-10-07 2013-10-15 Sanofi Pasteur Sa Stabilizing excipient for inactivated whole virus vaccine
WO2011121306A1 (en) * 2010-03-31 2011-10-06 Stabilitech Ltd. Stabilisation of viral particles
EP2689785B1 (en) * 2010-04-15 2021-05-19 Shin Nippon Biomedical Laboratories, Ltd. Method for generating dry vaccine powder formulation for inranasal delivery
GB201007207D0 (en) 2010-04-29 2010-06-16 Univ Cork Method
CA2801151A1 (en) 2010-06-01 2011-12-08 Novartis Ag Concentration of vaccine antigens with lyophilization
WO2011156641A2 (en) 2010-06-09 2011-12-15 Kaspar Roger L Microneedle arrays for active agent delivery
JP5808102B2 (ja) 2010-07-22 2015-11-10 コスメディ製薬株式会社 抗原を含有する経皮免疫製剤およびその製造方法
CA2808965C (en) 2010-08-20 2020-01-07 Theraject, Inc. Soluble needle arrays for delivery of influenza vaccines
JP5558311B2 (ja) 2010-10-27 2014-07-23 株式会社バイオセレンタック ワクチン抗原表皮デリバリー用溶解性３層マイクロニードル・アレイ・パッチ
US9089677B2 (en) 2011-01-25 2015-07-28 The Regents Of The University Of California Transcutaneous multimodal delivery system (TMDS)
BR112013027057A2 (pt) * 2011-04-21 2020-08-11 Trustees Of Tufts College composições e métodos para a estabilização de agentes ativos
KR102374576B1 (ko) 2011-05-17 2022-03-15 솔리제닉스, 인크. 열안정성 백신 조성물 및 그의 제조방법
US20130096532A1 (en) 2011-10-17 2013-04-18 Rutgers, The State University Of New Jersey Polymer-Based Micro-Needle Array Designs, Fabrication Processes, and Methods of Use Thereof for Drug Delivery
AU2012345777B2 (en) * 2011-11-30 2016-05-12 Kindeva Drug Delivery L.P. Microneedle device including a peptide therapeutic agent and an amino acid and methods of making and using the same
JP2015515474A (ja) 2012-04-03 2015-05-28 セラジェクト， インコーポレイテッド ワクチンの経頬送達のための溶解性微小針アレイ
US20130345638A1 (en) 2012-06-25 2013-12-26 Flugen, Inc. Multiple drug delivery device
US10130760B2 (en) 2013-03-15 2018-11-20 Incube Labs, Llc Multi-stage biodegradable drug delivery platform
AU2015343369B2 (en) 2014-11-03 2018-11-22 Georgia Tech Research Corporation Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus

Also Published As

Publication number Publication date
US10736840B2 (en) 2020-08-11
ES2897659T3 (es) 2022-03-02
RU2016111354A3 (enExample) 2018-07-16
JP2019163271A (ja) 2019-09-26
CA2923010A1 (en) 2015-03-12
JP2016535065A (ja) 2016-11-10
CN105579059A (zh) 2016-05-11
CN105579059B (zh) 2020-07-31
WO2015034924A1 (en) 2015-03-12
JP6611720B2 (ja) 2019-11-27
EP3041504A1 (en) 2016-07-13
RU2720808C2 (ru) 2020-05-13
US20160220483A1 (en) 2016-08-04
JP7358068B2 (ja) 2023-10-10
EP3041504B1 (en) 2021-08-25
EP3041504A4 (en) 2018-02-21
RU2016111354A (ru) 2017-10-09

Similar Documents

Publication Publication Date Title
JP7358068B2 (ja) 熱安定性ワクチン製剤及びマイクロニードル
Dumpa et al. Stability of vaccines
Kim et al. Formulation of microneedles coated with influenza virus-like particle vaccine
RU2560675C2 (ru) Стабилизирующий эксципиент для вакцины с инактивированными целыми вирусами
US10335479B2 (en) Methods and compositions for stabilizing dried biological materials
CA2680193C (en) Lyophilized preparation comprising influenza vaccine, and method for preparation thereof
Tian et al. Intradermal administration of influenza vaccine with trehalose and pullulan-based dissolving microneedle arrays
JP2016534070A (ja) 安定化ワクチンの製造のための新規方法
WO2023194699A2 (en) Vaccine composition
Beukema Intradermal administration of influenza accine ith trehalose and pullulan-based dissol ing microneedle arra s
WO2024236132A1 (en) Formulations to stabilize virus-based therapeutics
Edens Measles and polio vaccination using a microneedle patch to increase vaccination coverage in the developing world
HK1167604A (en) Stabilising excipient for inactivated whole-virus vaccines
HK1167604B (en) Stabilising excipient for inactivated whole-virus vaccines
HK1139076B (en) Lyophilized preparation comprising influenza vaccine, and method for preparation thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190820

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240802

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240802

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250820

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250820